Eiropas Savienība - angļu - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - all other therapeutic products - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron carboxymaltose 180 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - 50 mg/ml - ferric carboxymaltose 180 mg/ml - iron, parenteral preparations

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron carboxymaltose 180 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - 50 mg/ml - ferric carboxymaltose 180 mg/ml - iron, parenteral preparations

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron carboxymaltose 180 mg/ml - eq. iron 50 mg/ml - dispersion for injection/infusion - 50 mg/ml - ferric carboxymaltose 180 mg/ml - iron, parenteral preparations

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron sucrose - eq. iron 20 mg/ml - solution for injection/infusion - 20 mg/ml - iron sucrose 540 mg/ml - iron, parenteral preparations

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron sucrose - eq. iron 20 mg/ml - solution for injection/infusion - 20 mg/ml - iron sucrose - iron, parenteral preparations

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

vifor france s.a. - iron sucrose - eq. iron 20 mg/ml - solution for injection/infusion - 20 mg/ml - iron sucrose - iron, parenteral preparations

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

vifor (international) inc. - methoxy polyethylene glycol-epoetin beta (unii: lr3uxn0193) (methoxy polyethylene glycol-epoetin beta - unii:lr3uxn0193) - methoxy polyethylene glycol-epoetin beta 30 ug in 0.3 ml - mircera is indicated for the treatment of anemia associated with chronic kidney disease (ckd) in: limitations of use mircera is not indicated and is not recommended: mircera has not been shown to improve symptoms, physical functioning, or health-related quality of life. mircera is contraindicated in patients with: risk summary available data from a small number of published case reports and postmarketing experience with mircera use in pregnancy are insufficient to identify a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. chronic kidney disease is associated with maternal and embryo-fetal risks (see clinical considerations) . in animal reproduction studies, administration of methoxy polyethylene glycol-epoetin beta to rats and rabbits during pregnancy and lactation adversely affected offspring at doses 17-fold and greater than the recommended human dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated populatio

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ferric carboxymaltose -

Singapūra - angļu - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - iron(iii)-hydroxide polymaltose complex 357mg eqv iron (iii) - tablet, film coated - iron(iii)-hydroxide polymaltose complex 357mg eqv iron (iii) 100mg